证券代码：000908 证券简称：*ST 景峰 公告编号：2024-033 湖南景峰医药股份有限公司 二、董事会会议审议情况 与会董事审议并通过了下列议案： 1、《关于调整公司第八届董事会审计委员会成员构成的议案》 第八届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2024 年 5 月 23 日以电 子邮件、电话、即时通讯等方式发出了关于召开第八届董事会第二十八次会议的通 知。 2、公司第八届董事会第二十八次会议于 2024 年 5 月 29 日上午 9:00—11:00 以通讯方式召开。 3、会议应出席表决董事 6 人，实际出席表决董事 6 人。 4、会议由董事长叶湘武先生主持。 5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 表决结果：6 票同意，0 票反对，0 票弃权。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 特此公告 为完善公司治理结 ...

证券代码：000908 证券简称：*ST 景峰 公告编号：2024-030 湖南景峰医药股份有限公司 关于 2023 年度股东大会增加临时提案暨股东大会补充 通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南景峰医药股份有限公司（以下简称"公司"）于 2024 年 4 月 30 日在 《中国证券报》《证券时报》《上海证券报》《证券日报》和巨潮资讯网披露了 《关于召开 2023 年度股东大会的通知》（2024-023），公司定于 2024 年 5 月 30 日召开 2023 年度股东大会。 2024 年 5 月 19 日，公司董事会收到中国长城资产管理股份有限公司（以下 简称"长城公司"）出具的《关于提出湖南景峰医药股份有限公司 2023 年度股 东大会临时提案的告知函》：长城公司作为持有公司 12.92%的股东，提出以下临 时提案，请提交公司 2023 年度股东大会审议： 1、《关于拟向法院申请重整及预重整的议案》 本提案详见公司同日在巨潮资讯网披露的《关于股东提议增加股东大会临时 提案的公告》（公告编号：2024-031）。 2、《关于提名张莉 ...

关于股东提议增加股东大会临时提案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000908 证券简称：*ST 景峰 公告编号：2024-031 湖南景峰医药股份有限公司 湖南景峰医药股份有限公司（以下简称"公司"）董事会于 2024 年 5 月 19 日收到股东中国长城资产管理股份有限公司（以下简称"长城公司"）出具的《关 于提出湖南景峰医药股份有限公司 2023 年度股东大会临时提案的告知函》，长城 公司提议公司董事会将《关于拟向法院申请重整及预重整的议案》和《关于提名 张莉为公司第八届董事会非独立董事候选人的议案》两项临时提案提交至公司 2023 年度股东大会审议。 因公司目前存在下列情况： 1、公司重要子公司目前处于临时停产状态，公司股票自 2024 年 4 月 30 日 起已被深圳证券交易所实施其他风险警示。 2、公司 2021 年至 2023 年连续三个会计年度经审计扣除非经常性损益前后 净利润孰低者均为负值，且 2023 年度审计报告显示公司持续经营能力存在不确 定性。 3、公司及子公司存在因金融借款合同纠纷、资金借款合同纠纷、 ...

证券代码：000908 证券简称：*ST 景峰 公告编号：2024-029 湖南景峰医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 1、公司已被实施退市风险警示及其他风险警示。 公司 2023 年度经审计期末净资产为负值，公司股票被实施退市风险警示。 大信会计师事务所（特殊普通合伙）对公司 2023 年度内部控制情况出具了 否定意见的内部控制审计报告，公司股票被叠加实施其他风险警示。 公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值，且最 近一年审计报告显示公司持续经营能力存在不确定性，公司股票被叠加实施其他 风险警示。 2、公司是否进入预重整或重整程序尚存在重大不确定性 目前，山东省龙口市人民法院准许申请人吴中苏州太湖国家旅游度假区福坤 古典家具厂撤回对公司的预重整申请，终结公司预重整程序。2024 年 4 月 22 日， 公司收到申请人彭东钜送达的《关于对湖南景峰医药股份有限公司申请预重整及 重整的通知》，申请人已向湖南省常德市中级人民法院申请对公司进行重整，并 同时申请启动预重整程序。公 ...

深 圳 证 券 交 易 所 关于对湖南景峰医药股份有限公司 2023 年年报的问询函 公司部年报问询函〔2024〕第 141 号 湖南景峰医药股份有限公司董事会： 我部在对你公司 2023 年年度报告（以下简称"年报"）进 行审查的过程中，关注到如下事项： 1、大信会计师事务所（特殊普通合伙）（以下简称"年审 会计师"）对你公司 2023 年度财务报告出具了保留意见，保留 意见涉及固定资产账面价值的准确性、预计负债计提的恰当性、 持续经营能力重大不确定性。年审会计师无法判断"太湖之星" 房产项目账面原值的准确性，亦无法判断折旧计提与减值准备计 提的合理性，以及对财务报表的影响。你公司"16 景峰 01"债 券已多次展期，最近一次约定展期至 2024 年 6 月 30 日。根据债 券发行协议约定，如果你公司截至最近一次展期日不能兑付本金， 将自2021 年10 月起支付违约金8,635.88万元，截至 2023年末， 你公司已计提违约金 2,305 万元，年审会计师无法判断未足额计 1 提违约金的恰当性。截至 2023 年末，你公司未分配利润 -117,730.02 万元，归属于母公司的所有者权益为负数，资产负 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥100,575,702.29, a decrease of 42.87% compared to ¥176,056,130.03 in the same period last year[3] - Net profit attributable to shareholders was ¥3,505,293.50, representing a significant increase of 174.14% from ¥1,278,629.96 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,848,275.03, up 191.11% from ¥634,895.22 in the previous year[3] - The net profit for Q1 2024 is CNY 4,999,711.10, a decrease of 42.5% compared to CNY 8,743,250.95 in Q1 2023[15] - The total comprehensive income for Q1 2024 is CNY 5,033,635.69, a decrease of 38.5% compared to CNY 8,142,115.82 in Q1 2023[15] Cash Flow and Assets - The net cash flow from operating activities decreased by 36.55% to ¥8,644,488.81 from ¥13,623,933.97 in the same period last year[3] - Cash and cash equivalents increased to CNY 14,923,877.12 from CNY 13,165,034.76 at the beginning of the period[12] - The cash flow from operating activities shows a net increase of CNY 8,644,488.81, compared to CNY 13,623,933.97 in the same period last year, reflecting a decline of 36.5%[16] - The cash flow from investing activities shows a net outflow of CNY 415,900.00, an improvement from a net outflow of CNY 5,259,594.09 in Q1 2023[16] Expenses and Liabilities - Total operating costs for Q1 2024 were CNY 103,667,185.25, down 38.6% from CNY 168,775,870.62 in the previous year[14] - The company experienced a 62.15% decrease in R&D expenses, attributed to lower investment compared to the same period last year[6] - The company incurred operating expenses of CNY 139,084,711.87, which is a reduction from CNY 194,283,595.58 in the previous year[16] - Total liabilities rose to CNY 1,248,555,275.02, compared to CNY 1,214,026,778.21 at the start of the quarter[12] Assets and Equity - Total assets at the end of the reporting period were ¥1,099,908,516.64, reflecting a growth of 3.73% from ¥1,060,346,384.15 at the end of the previous year[3] - The company's equity attributable to shareholders improved to -¥45,971,788.89, a 7.12% increase from -¥49,494,383.93 at the end of the previous year[3] - Accounts receivable increased to CNY 92,055,291.34, up from CNY 77,481,859.65 at the start of the quarter[12] - Inventory decreased slightly to CNY 63,623,193.84 from CNY 64,577,591.95 at the beginning of the period[12] - Deferred tax assets increased to CNY 12,552,242.04 from CNY 10,409,234.18 at the beginning of the period[12] Other Income and Government Subsidies - The company received government subsidies amounting to ¥2,651,768.60, contributing to a 363.96% increase in other income[6] - The company reported a 252.62% increase in prepayments, primarily due to increased procurement during the period[6] Earnings Per Share - Basic and diluted earnings per share increased to ¥0.0040, a rise of 166.67% from ¥0.0015 in the previous year[3] - The company reported a basic and diluted earnings per share of CNY 0.0040, up from CNY 0.0015 in Q1 2023, indicating a significant improvement[15] Additional Notes - The company has not reported any new product launches or significant market expansions during this quarter[18] - The financial report for Q1 2024 has not been audited[18]

Financial Performance - The company's operating revenue for 2023 was ¥656,893,837.84, a decrease of 21.86% compared to ¥840,657,161.99 in 2022[21]. - The net profit attributable to shareholders for 2023 was ¥215,144,077, reflecting a significant decline of 75.54% from ¥128,162,925 in 2022[21]. - The net cash flow from operating activities decreased by 71.55% to ¥35,063,943.4 in 2023, down from ¥123,266,701 in 2022[21]. - The basic earnings per share for 2023 was -¥0.2445, a drop of 75.52% compared to -¥0.1457 in 2022[21]. - Total assets as of the end of 2023 were ¥1,060,346,384.15, a decrease of 27.25% from ¥1,468,474,400.00 in 2022[22]. - The net assets attributable to shareholders were -¥49,494,383.9 in 2023, a decline of 130.04% from ¥177,927,696 in 2022[22]. - The company reported a total revenue of ¥415,018,671.17 from sustainable core business operations after excluding non-recurring income, compared to ¥818,141,263.01 in 2022[23]. - The first quarter of 2023 saw operating revenue of ¥176,056,130.03, while the fourth quarter revenue dropped to ¥103,060,034.15[27]. - The pharmaceutical segment generated ¥629,709,977.39, accounting for 95.86% of total revenue, with a year-on-year decrease of 20.07%[49]. - The injection product revenue was ¥376,649,748.03, representing 57.34% of total revenue, down 27.39% year-on-year[50]. Internal Control and Governance - The company reported a significant internal control deficiency during the reporting period, leading to a negative opinion in the internal control audit report[4]. - The audit report issued by DaXin Accounting Firm contains a qualified opinion, and the board has provided detailed explanations regarding related matters[4]. - The company identified 3 significant internal control deficiencies in financial reporting during the reporting period[126]. - The company plans to strengthen internal control self-assessment and internal audit to prevent similar issues from recurring[127]. - The company has implemented a robust internal control system to enhance management and operational efficiency[96]. - The internal control evaluation report indicates that 91.40% of the total assets and 97.75% of the total revenue of the company are included in the evaluation scope[131]. - There are three major defects identified in financial reporting internal controls, which may lead to significant deviations from control objectives[133]. - The company has not implemented effective supervision and management of its investments, leading to delays in recovering performance compensation from invested entities[134]. - The company has acknowledged and addressed issues related to the improper use of fundraising during 2017-2020[77]. Research and Development - The company is committed to increasing R&D investment in response to national policies promoting high-end, intelligent, and green transformation in the pharmaceutical industry[33]. - The company has a clear R&D strategy with a rich pipeline, including products for cardiovascular, oncology, and pain management[46]. - The company is actively pursuing research and development projects, including a Class 1 new drug and various complex injection projects, to ensure compliance with NMPA and FDA regulations[83]. - The company is enhancing its research and development capabilities in the sodium hyaluronate field, aiming to introduce new products, including those for cosmetic applications[45]. - The company has achieved consistency evaluation for several products, which will support market expansion and meet demand[82]. - The company is focusing on high-end formulation research and production platforms, including liposomes and nanoemulsions, to enhance its product offerings[45]. - The company has established a scientific project initiation and tracking mechanism to mitigate R&D project failure risks[88]. Market Strategy and Operations - The company emphasizes a procurement model that prioritizes risk control, cost minimization, and quality assurance, ensuring reliable raw material sources[36]. - The production management follows a sales-driven production model, aligning production schedules with sales plans and inventory data[37]. - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding the sales team to enhance market presence[38]. - The company is actively exploring the use of new media and e-commerce technologies to enhance market reach and penetrate deeper into the terminal market[38]. - The company plans to expand its market presence in private hospitals and lower-tier medical markets, expecting stable sales growth[46]. Environmental Compliance - The company strictly adheres to national and local environmental protection laws and regulations during its operations[138]. - The company has successfully maintained compliance with all monitored pollutants, including suspended solids and total phosphorus, with no exceedances reported[144]. - The company has implemented measures to ensure that all wastewater and atmospheric emissions are within the regulatory limits, demonstrating commitment to environmental sustainability[145]. - The company continues to invest in environmental compliance and sustainability initiatives, reflecting its long-term strategic goals[144]. - The company has established emergency response plans for environmental incidents and reported them to the relevant environmental protection departments[159]. Financial Challenges and Restructuring - The company reported a negative net asset value as of the end of the 2023 audit period, which may lead to a delisting risk warning according to Shenzhen Stock Exchange regulations[179]. - The company has been involved in a bankruptcy pre-restructuring application due to its inability to repay debts, with a recent application for restructuring submitted to the Hunan Intermediate People's Court[180]. - The company plans to sell subsidiary equity and restructure assets to generate funds for bond repayment[169]. - The company is focused on enhancing its internal control and operational standards to protect shareholder interests amid ongoing financial challenges[172]. Shareholder and Board Matters - The company held its first temporary shareholders' meeting in 2023 with a participation rate of 14.32%[98]. - The company appointed two new independent directors, Liu Ting and Zhai Peiyi, during the extraordinary shareholders' meeting held on April 24, 2023[101]. - The total remuneration for the board of directors, supervisors, and senior management in 2023 amounted to 1.5598 million yuan[111]. - The company received a public reprimand from the Shenzhen Stock Exchange in January 2022 for issues related to corporate governance[109]. - The company has a diverse board with members holding various significant positions in other pharmaceutical companies and financial institutions[103].

湖南景峰医药股份有限公司（以下简称"公司"）经公司财务部门初步测算， 预计 2023 年度期末净资产为-6,000 万元至-3,000 万元，详见公司披露的《2023 年度业绩预告》（公告编号：2024-004）。根据《深圳证券交易所股票上市规则》 第 9.3.1 条第一款第（二）项的规定，上市公司出现"最近一个会计年度经审计 的期末净资产为负值，或追溯重述后最近一个会计年度期末净资产为负值"的情 形，公司股票交易将在 2023 年年度报告披露后被实施退市风险警示（在公司股 票简称前冠以"*ST"字样）。根据《深圳证券交易所股票上市规则》第 9.3.2 条 的规定："上市公司预计将出现本规则第 9.3.1 条第一款第（一）项至第（三） 项情形的，应当在相应的会计年度结束后一个月内，披露公司股票交易可能被实 施退市风险警示的风险提示公告，并在披露年度报告前至少再披露两次风险提示 公告。" 公司已于 2024 年 1 月 30 日披露了《关于公司股票可能被实施退市风险警示 的提示性公告》（公告编号：2024-005）。 公司已于 2024 年 3 月 30 日披露了《关于公司股票可能被实施退市风险警示 的提示性公 ...

证券代码：000908 证券简称：景峰医药 公告编号：2024-015 湖南景峰医药股份有限公司 关于预重整事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，湖南景峰医药股份有限公司（以下简称"公司"或"景峰医药"）收 到山东省龙口市人民法院（以下简称"龙口法院"）下发的《决定书》【（2023） 鲁0681破申（预）3号之三】，龙口法院准许申请人福坤家具厂撤回对景峰医药 的预重整申请，终结景峰医药预重整程序。同期公司收到债权人彭东钜（以下 简称"申请人"）送达的《关于对湖南景峰医药股份有限公司申请预重整及重整 的通知》，申请人因公司不能清偿到期债务且明显缺乏清偿能力，于2024年4月 22日向湖南省常德市中级人民法院（以下简称"常德中院"或"法院"）申请对 公司进行重整，并同时申请启动预重整程序。现将公司预重整事项进展情况公 告如下： 一、公司被申请预重整的前期进展 2023年11月16日，公司收到龙口法院送达的《山东省龙口市人民法院通知 书》【（2023）鲁0681破申（预）3号之二】、《山东省龙口市人民法院决定书》【（2023） 鲁06 ...

摩根士丹利证券（中国）有限公司 关于 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 债券代码：112468 债券简称：16景峰01 2024 年 4 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本 报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、 "公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作其他任 何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证券不承担 任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管 理人，持续密切关注对该等债券 ...